• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Bedaquiline efficacious in treating multidrug resistant tuberculosis: phase 2 trial

byAli ShahbazandXu Gao
August 21, 2014
in Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. After 24 weeks, patients who were given bedaquiline yielded a faster sputum culture conversion rate when compared to placebo. Both groups were given a five-drug, second-line antituberculosis background regimen. 

2. More deaths occurred in patients treated with bedaquiline compared to treatment with placebo. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Although current antibiotic treatments have been successful in treating tuberculosis, the recent rise in multidrug resistant strains has proven to be a major challenge. Of the 8.6 million cases of tuberculosis in 2012, 450,000 were due to multidrug-resistant strains. In late 2012, for the first time in decades, a novel tuberculosis drug was approved by the FDA. This drug, called bedaquiline, works by inhibiting mycobacterial ATP synthase. Stage 1 of the TMC207-C208 phase 2b study found that the addition of bedaquiline to the preferred therapy for 8 weeks resulted in increased antibacterial activity.

In this stage 2 of the phase 2b trial, the authors further evaluated the efficacy and safety of bedaquiline with a longer treatment duration of 24 weeks. Results were consistent with that of the previous trial: the addition of bedaquiline to a conventional five-drug background regimen led to faster and more culture conversions at 120 weeks when compared to placebo plus the same background regimen. Notably, more deaths occurred in the group treated with bedaquiline as compared to placebo, although data was statistically insignificant.

While the results are promising, the study was limited by the small sample size, only 79 patients received bendaquiline. In addition, the study also excluded patient receiving antiretroviral therapy for HIV infection. The increased mortality rate with bendaquiline is also concerning.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 25

The Scan by 2 Minute Medicine®: Company Cuts TB Testing Cost, Guillain-Barre Syndrome Struggles for Stevens, Medical Abortion Tests, and Blood Supply Shortages

#VisualAbstract: Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India

Click to read the study, published today in NEJM

Click to read the accompanying editorial in NEJM

Relevant Reading: Drug -resistant tuberculosis

In-Depth [randomized controlled trial]: This study recruited patients 18-65 years old who were recently diagnosed with pulmonary multidrug resistant tuberculosis. Trial sites were set up across 8 countries around the world. The patients were randomized to receive either bedaquiline or a placebo in addition to a five-drug, second-line anti-tuberculosis background regimen.

60 patients discontinued prematurely as a result of adverse events encountered or withdrawal of consent. The median time to sputum-culture conversion was faster in the bedaquiline compared to the placebo group of 2.44 (95% confidence interval [CI], 1.57 to 3.80, P< 0.0001). Additionally, it was supported that more patients in the bedaquiline group rather than the placebo group had confirmed culture conversion at both 24 and 120 weeks: 52 of 66 patients (79%) and 38 of 66 (58%) in the two groups, respectively, at 24 weeks (P= 0.008). In the bedaquiline group, 10 of 79 (13%) patients died as compared to 2 of 81 (2%) in the placebo group (P=0.02).

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Bedaquilinetuberculosis
Previous Post

Active commuting associated with a lower BMI, body fat

Next Post

Lenalidomide may boost prognosis in diffuse large B-cell lymphoma

RelatedReports

The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 25

October 5, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Company Cuts TB Testing Cost, Guillain-Barre Syndrome Struggles for Stevens, Medical Abortion Tests, and Blood Supply Shortages

October 3, 2023
#VisualAbstract: Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India
StudyGraphics

#VisualAbstract: Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India

August 15, 2023
StudyGraphics

#VisualAbstract: Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

March 23, 2023
Next Post
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Lenalidomide may boost prognosis in diffuse large B-cell lymphoma

Afatinib shows increased progression-free survival in non-small-cell lung cancer

New method may predict response to chemotherapy for lung cancer

Single course intravenous immunoglobulin ineffective at controlling severe solar urticaria

Single course intravenous immunoglobulin ineffective at controlling severe solar urticaria

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Seriesâ„¢ textbook.

Subscription Options

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • A Begginer’s Guide to Understanding Odds Ratios, Confidence Intervals, and P-values
  • #VisualAbstract: Intravenous Levothyroxine Does Not Increase the Number of Heart Transplants in Unstable Brain-Dead Potential Heart Donors
  • #VisualAbstract: Dapagliflozin does not reduce albuminuria in patients with heart failure and type 2 diabetes (DAPPER study)
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classicsâ„¢
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options